Abstract
Currently the majority of neurological clinical trials are initiated by industry. Their purpose is largely promotional. There is a need for conducting investigator-initiated trials, which are disease oriented, and try to answer questions related to problems in diagnosis, investigation and therapy, in addition to the comparative benefits individual preparations. Head to head studies of new drugs also need consideration, as the majority of trials leading to Government approval are not necessarily designed to answer questions of clinical concern. A uniform procedure to correct this situation may represent a positive step in enhancing the stature and quality of neurological research in Australia, at no significant loss of funding for the investigator.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
